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httpcense.Abstract Background: Minimal residual disease (MRD) studies in adult acute lymphoblastic leu-
kemia (ALL) give highly signiﬁcant prognostic information superior to other standard criteria as
age, gender and total leucocytic count (TLC) in distinguishing patients at high and low risk of
relapse.
Objectives: We aimed to determine the value of MRD monitoring by ﬂowcytometry (FCM) in pre-
dicting outcome in adult Precursor ALL patients.
Patients and methods: Bone marrow (BM) samples were analyzed by 4-color FCM collected at
diagnosis and after induction therapy (MRD1) to correlate MRD positivity with disease free sur-
vival (DFS) and overall survival (OS).
Results: Study included 57 adult ALL patients (44 males and 13 females) with a median age of
22 years (18–49). DFS showed no signiﬁcant difference with age, gender and initial TLC
(p= 0.838, 0.888 and 0.743, respectively). Cumulative DFS at 2 years was 34% for B-lineage
ALL (n: 35) and 57% for T-lineage ALL (n: 18) (p= 0.057). Cumulative DFS at 2 years wasrtment of Clinical Pathology,
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136 M.A. Samra et al.7% for MRD1 positive (high risk, HR) versus 57% for MRD1 negative patients (Low risk, LR)
(p< 0.001). Cumulative DFS at 2 years was 29% for HR patients (n: 26) versus 55% for LR (n:
27) according to GMALL classiﬁcation (p= 0.064). Cumulative OS did not differ according to
age, gender and TLC (p= 0.526, 0.594 and 0.513, respectively). Cumulative OS at 2 years was
36% for B ALL (n: 39) versus 77% for TALL (n: 18) (p= 0.016) and was 49% for Philadelphia
chromosome (Ph) negative patients versus 0% for Ph-positive patients (p< 0.001). Regarding
MRD1, OS at 2 years was 18% for MRD1 HR (n: 17) versus 65% for MRD1 LR (n: 38)
(p< 0.001). OS was 35% for high-risk patients (n: 30) and 62% for low-risk patients (n: 27) clas-
siﬁed according to GMALL risk stratiﬁcation (p= 0.017).
Conclusion: MRD by FCM is a strong independent predictor of outcome in terms of DFS and OS
and is a powerful informative parameter in guiding individual treatment in ALL patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Based on retrospective analyses of large cohorts of patients,
conventional pre-therapeutic risk criteria including age, ele-
vated total leucocytic count (TLC) at diagnosis, adverse immu-
nophenotypic features and cytogenetic as well as molecular
aberrations provide the basis for upfront risk stratiﬁcation in
current treatment protocol [1]. The classical deﬁnition of
remission in ALL based on cytomorphology provides only
superﬁcial information about the effectiveness of the treatment
because, within the patient group that achieves remission, mor-
phology is unable to discriminate between patients at high risk
of relapse and those with excellent prognosis. Therefore, sensi-
tive techniques for Minimal residual disease (MRD) detection
were developed for detection of lower frequencies of malignant
cells during and after treatment [2]. MRD measurement by
ﬂow cytometry (FCM) is based on the detection of leukemia
associated immunophenotypes (LAP) that can be used to dis-
tinguish them from normal hematopoietic cells [1].
The source of relapse in adult precursor ALL patients is the
persistence of MRD that is undetectable by standard diagnos-
tic techniques. Several studies have shown that detection of
MRD in childhood and adult ALL is an independent risk
parameter of high clinical relevance, both in de novo and re-
lapsed ALL as well as in ALL undergoing hematopoietic stem
cell transplantation [3–5] and suggest that detection of MRD
at an early time point during/following induction or consolida-
tion therapy has emerged as a powerful and independent pre-
dictor of prolonged event free survival (EFS) in children and
adults with ALL [6,7]. Consequently, an increasing number
of treatment protocols use MRD as a tool for treatment strat-
iﬁcation. However, the decisions for selection of one MRD
methodology over another are complex and dependent upon
a number of factors in our institution especially time to deliver
results, expertise and resources.
In this study, we aimed to determine the value of MRD
monitoring by FCM in adult precursor ALL patients especially
post-induction of cytoremission in order to predict impending
relapse to start preemptive salvage treatment in time.Patients and methods
All eligible adults diagnosed as de novo precursor ALL pa-
tients who presented to the Medical Oncology Department
of Egyptian National Cancer Institute (NCI), Cairo
University, in the time period from April 2006 to April 2007were recruited in this study. The study was approved by the
IRB of the NCI.
Pretreatment evaluation included thorough history and full
clinical examination, complete blood count (CBC), bone mar-
row (BM) aspiration for morphology and cytochemistry and
FCM immunophenotyping. Liver and kidney functions tests,
uric acid level, serum electrolytes, and cerebrospinal ﬂuid
(CSF) examination were also done in addition to cytogenetics
for Ph’ chromosome, chest radiographs, abdominal ultra-
sound, ECG and echocardiography. Informed consents were
obtained from all patients before inclusion into the study.
Eligibility criteria included (1) age from 18 to 50 years, (2)
all FAB subtypes except L3, (3) all immunophenotypes except
Mature B subtype, (4) ECOG performance status 62, (5) no
other malignancy, (6) no prior chemotherapy or radiotherapy,
and (7) no medical contraindications.
MRD assessment FCM was done at diagnosis to detect
LAP and for detection of MRD after induction therapy
(MRD1) and during maintenance therapy (MRD) using a
Coulter EPICS XL-MCL ﬂow cytometer system (Coulter Cor-
poration, Hialeah) and a reagent system (Coulter Diagnostics,
Hialeah). Surface staining ﬂuorescent labeled mouse monoclo-
nal antibodies against human T, B, myeloid antigens and iso-
typic controls were obtained from Becton Dickenson
(Mountain View, California). Intracellular staining was done
using IntaPrep permeabilization reagent from the Beckman
Coulter by which cells were ﬁxed with reagent 1(ﬁxation re-
agent using formaldehyde), after washing, permeability was in-
duced with reagent 2 (using Saponine for permeability) and
remaining erythrocytes were lysed [8]. The following monoclo-
nal antibodies were used for four color combinations for the
detection of MRD [9]
 Precursor B-ALL: TdT/CD10/CD19/CD 45; CD10/CD20/
CD19/CD 45; CD34/CD38/CD19/CD 45; CD34/CD22/
CD19/CD 45; CD19/CD34/CD45; CD10/CD20/CD22/
CD 45.
 T-ALL: TdT/CD1/ cyt CD3; TdT/ cyt CD3/ CD7; CD4/
CD8/ CD3/CD45.
At least 3 · 105 ungated events were collected and analyzed
[9]. Minimum target sensitivity for quantifying MRD was de-
ﬁned as the ability to detect 30 clustered MRD events in 3x 105
total cellular events (0.01%).Cut off point of MRD1 was <10
3 (0.1%) and for MRD at any time point was <104 (0.01%)
[10,11]. Risk groups were deﬁned as MRD low risk (MRD-
LR) for patients with MRD< 104 at all examined time
Table 1 Patients’ characteristics of the 57 adult precursor
ALL.
Age No (%)
Mean ± SD 24.39 ± 6.98
<25 37 (64.9%)
25–49 20 (35.1%)
Sex
Female 13 (22.8%)
Male 44 (77.2%)
Immunophenotyping
B-ALL 39 (68.4%)
Pro B-ALL 2 (3.5%)
C-ALL 28 (49.1%)
Pre B-ALL 9 (15.8%)
T-ALL 18(31.6%)
Early T-ALL 5 (8.8%)
Intermediate T-ALL 11 (19.3%)
Mature T-ALL 2 (3.5%)
Leukocyte count (·109 L)
<10 14 (24.6%)
10–49 19 (33.3%)
50–100 10 (17.5%)
>100 14 (24.6%)
BM cellularit
Hypercellular 36(63.2%)
Normocellular 15 (26.3%)
Hypocellular 6 (10.5%)
BM morphology
L1 5 (8.8%)
L2 34 (59.6%)
Not assessed 18 (31.6%)
Cytogenetics
Normal 37(65%)
Philadelphia positive 7 (12.3%)
Unknown 13 (22.8%)
Initial CSF examination
Positive for blast cells 3 (5.2%)
Negative for blast cells 54 (94.8%)
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tients with MRD> 104 at any time-point.
Treatment plan
Standard (low)-risk group
(1) Prephase (TLC> 250x109/L or marked organomegaly):
vincristine 2 mg I.V. (D1), prednisone 60 mg/m2 P.O
(D1–7).
(2) Phase I induction: vincristine 2 mg I.V. (D1, 8, 15, 22),
daunorubicin (or adriamycin) 45 mg/m2 (D1, 8, 15,
22), L-Asparaginase 5000 U/m2 (D15–28), prednisone:
60 mg/m2 P.O (D1–28), methotrexate 15 mg intrathecal
(D1). All patients received allopurinol 600 mg/day in
addition to intravenous ﬂuids 3 L/day during induction
therapy as management of hyperleukocytosis.
(3) Cranial prophylaxis: cranial irradiation: 24 Gy + meth-
otrexate 15 mg intrathecal given as 4 doses (twice/week).
(4) Phase II induction: Cyclophosphamide: 650 mg/m2 D 1,
14, 28 + cytosine arabinoside 75 mg/m2 D 3, 4, 5, 6, and
D 9, 10, 11, 12 and D 16, 17, 18, 19.
(5) Phase I consolidation: vincristine 2 mg I.V. (D1, 8, 15, 22),
daunorubicin (or adriamycin) 25 mg/m2 (D1, 8, 15, 22),
prednisone: 60 mg/m2 P.O. D1–28 in addition to triple
intrathecal injection of cytosine arabinoside 40 mg,
methotrexate 15 mg and dexamethasone 4 mg (D1).
(6) Phase II consolidation: Cyclophosphamide: 650 mg/m2
I.V. (D 1), cytosine arabinoside 75 mg/m2 I.V. (D 3, 4,
5, 6 and D 9, 10, 11, 12) then 100 mg/m2 I.V. (D 25,
26, 27, 30), etoposide 100 mg/m2 (D 25, 26, 27, 30)
and triple intrathecal injection (as before) (D1).
(7) Maintenance: Patients classiﬁed as MRD-LR at end of
consolidation therapy received maintenance treatment
for two years while MRD-HR patients were planned to
receive maintenance treatment for three years. Mainte-
nance therapy included 6-Mercaptupurine 60 mg/m2
P.O. daily, methotrexate 20 mg/m2 I.V. once weekly
and triple intrathecal therapy (as before) every 2 months.
High-risk group
(1) Prephase and induction therapy (phase I and II): as in
standard risk group.
(2) Post-induction therapy HLA-typing was performed and
patients were referred for allogeneic stem cell transplanta-
tion. In case of no identical donor found, patients received
one course of HAM regimen (cytosine arabinoside
1.5 gm/m2/12 h IV days 1–3, and mitoxantrone: 12 mg/
m2 IV days 3–5 with mitoxantrone given before cytosine
arabinoside on day 3) then continued consolidation and
maintenance treatment as in the MRD-LR group.
Statistical analysis
All analyses were performed using the statistical package for
the social sciences (SPSS software 17; SPSS Inc., Chicago,
USA) [12]. Analytical tests used included chi-square test forcomparing two qualitative variables. Comparison of means
of two groups was done by student’s t-test for unpaired series
and by paired t-test when a subject was taken as his own con-
trol. Survival analysis and analysis of duration of complete
remission were done using Kaplan Meier analysis. Correlation
between quantitative variables was done by the r-test diagram-
matically represented by scatter dot diagram. Signiﬁcance level
of 0.05 was used in all statistical tests.
Results
This work included 57 adult Precursor ALL [44 males and 13
females] patients. Median age was 22 years. Thirty-seven pa-
tients had an age range from 18 to 24 years while 20 patients
were between 25 and 49 years.
Patients’ characteristics at diagnosis are shown in table 1
Response to induction chemotherapy
Fifty out of 57 (87.7%) patients achieved morphological
complete response (CR) within 4 weeks. 4/7 patients who
138 M.A. Samra et al.failed to achieve CR did not achieve any kind of response (i.e.
primary refractory disease) and were all Philadelphia positive.
In precursor B-ALL group, 34/39 (87.1%) achieved CR
including 2/2 pro B-ALL (100%), 24/28 (85.7%) c-ALL and
8/ 9 (88.8%) pre B-ALL patients. In the T-ALL phenotype,
16/18 (88.8%) patients achieved CR within 4 weeks of induc-
tion including 4/5 (80%) early T-ALL, 10/11 (90.9%) interme-
diate T-ALL and 2/2 (100%) mature T-ALL phenotype. Only
3/7 Ph + patients (42.8%) could achieve CR within 4 weeks of
induction therapy.
Risk stratiﬁcation
According to the GMALL risk stratiﬁcation [13], 27/57 pa-
tients (47%) were classiﬁed as low (standard) risk and 30/57
patients (53%) as high risk.
Evaluation of MRD
According to MRD1 positivity, 38/55 evaluable patients
(69%) were classiﬁed as Low risk and 17 patients (31%) as
high risk. Patients were classiﬁed according to overall MRD
into high risk (MRD positive at any point) and low risk
MRD (negative all through therapy). From the 55 evaluable
patients, 21 (38%) were classiﬁed as MRD-HR and 34 (62%)
were classiﬁed as MRD-LR.
Disease-free survival (DFS) (Table 2)
The cumulative DFS at 2 years for the whole studied group
was 42% with a median of 18 months. Cumulative DFS at
2 years was 48% for L2 while 1/5 of L1 cases only remained
disease free (p 0.010). Cumulative DFS at 2 years was 34%
for B-lineage ALL (n: 35) with a median of 12 months com-
pared to 57% for T-lineage ALL (n: 18) with median of
30 months (p= 0.057). Considering response to chemother-
apy, the 2-year DFS was 44% for 50 patients who achieved
CR within 4 weeks of induction chemotherapy while 2/3 pa-
tients who failed to achieve CR died. Cumulative DFS atTable 2 Cumulative DFS at 2 years of different ALL patients’ cate
Factor Number of cases Numb
All cases 53 32
Age <25 36 21
25+ 17 11
Sex Female 12 7
Male 41 25
Immunophenotyping B-ALL 35 24
T-ALL 18 8
Leucocyte counts <50 32 19
50+ 21 13
BM cellularity Hyper 33 21
Normo 6 4
Hypo 14 7
BM morphology L1 5 5
L2 32 16
Cytogenetics Normal 37
Ph + ve 3
MRD1 HR 14 14
LR 38 17
GMALL HR 26 19
LR 27 132 years was 57% for MRD1-LR (n: 38) (median 40 months)
versus 7% for MRD1-HR patients (n: 14) (median 7 months)
(p< 0.001) (Fig. 1). Regarding GMALL classiﬁcation, Cumu-
lative DFS at 2 years for LR patients (n: 27) was 55% (median
40 months) insigniﬁcantly higher than that of HR patients (n:
26) (29%, median 13 months) (p 0.064) (Fig. 2). Neither age,
gender nor BM cellularity correlated separately with DFS
(p= 0.838, 0.888 and 0.743 respectively).Overall survival (OS) (Table 3)
Cumulative OS at 2 years for the whole studied group was
49% with a median of 22 months. Cumulative OS at 2 years
was 20% for L1 and 55% for L2 (p= 0.053). Cumulative
2 years OS for B-lineage ALL was 35.6% versus 77% for T-
lineage ALL (p= 0.016) and was 49% for Ph-negative pa-
tients (n: 37) versus 0% for Ph- positive patients (n: 7)
(p< 0.001). Cumulative 2 year OS was 51% for patients
who achieved CR within 4 weeks of induction chemotherapy
compared to 29% for those who failed CR (p= 0.0007).
The cumulative 2 years OS was 65% forMRD1-LR (n: 38) ver-
sus 18% for MRD1-HR (n: 17) (p< 0.0001) (Fig. ure3).
Regarding GMALL classiﬁcation, Cumulative OS at 2 years
was higher for LR patients (n: 12); 63% versus 35% for HR
patients (n: 22) (p 0.017) (Fig. 4). Neither age, gender, TLC
nor BM cellularity correlated with OS (p= 0.526, 0.594,
0.513 and 0.551, respectively).MRD associated risk factors
Regarding B ALL, L1 morphology showed signiﬁcant associ-
ation with MRD1 HR (80%) than L2 cases (26%) (p= 0.035).
In addition, Ph chromosome positivity showed a near signiﬁ-
cant association with MRD1-HR (83%) versus Ph negative
cases (35%) (p= 0.067). Neither age, gender, immunopheno-
type nor TLC correlated with MRD risk (p= 0.644, 1.000,
0.394 & 0.171, respectively).gories.
er of events DFS p-Value
2 years (%) Median (months)
42.3 18
42.6 18
41.2 16 0.838
41.7 15
42.6 19 0.888
34.0 12
57.7 30 0.057
46.5 18
34.8 16 0.743
34.2 15
50.0 24
57.1 30 0.633
20.0 8
48.0 24 0.010
7.1 7
56.8 40 <0.001
29.3 13
55.1 40 0.064
Figure 1 DFS of the 57 adult ALL patients according to MRD1.
Figure 2 DFS of the 57 adult ALL patients according to GMALL classiﬁcation.
Table 3 Cumulative OS at 2 years of different ALL patients’ categories.
Factor Number of cases Number of events OS p-Value
2 years (%) Median (months)
All cases 57 34 48.8 22
Age <25 37 21 52.9 25
25+ 20 13 40.0 14 0.526
Sex Female 13 7 53.8 25
Male 44 27 49.4 22 0.594
Immunophenotyping B-ALL 39 27 35.6 15
T-ALL 18 7 76.9 40 0.016
Leucocyte counts <50 33 19 51.5 25
50+ 24 15 43.5 22 0.513
BM cellularity Hyper 36 23 46.3 16
Normo 15 3 66.7 26
Hypo 6 8 60.0 40 0.551
BM morphology L1 5 5 20.0 12
L2 34 18 54.7 26 0.053
Cytogenetics Normal 37 23 48.6 22
Ph + ve 7 7 0 (14 m) 6 <0.001
MRD1 HR 17 16 17.6 10
LR 38 16 64.8 – <0.001
GMALL HR 30 22 35.0 15
LR 27 12 62.6 – 0.017
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Figure 3 OS of the 57 adults ALL patients according to MRD1.
Figure 4 OS of the 57 adults ALL patients according to GMALL classiﬁcation.
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Thirty-four patients died; among them 26 died from disease re-
lapse, 2 died from fungal infections, 4 patients died from pri-
mary refractoriness, 1 patient died from fulminant HBV
infection and 1 patient died from pulmonary embolism.
Discussion
Among 57 ALL patients, FCM revealed 39 patients with B-
ALL (68%) and 18 (31.6%) with T phenotype which was al-
most comparable to others [14,15]. Precursor B-ALL patients
achieved a CR rate of 87% which was similar to T-ALL pa-
tients (89%); however OS at 2 years was 36% for B-lineage
versus 77% for T-lineage ALL (p= 0.016), a result also com-
parable to others [14,16]. Cumulative DFS at 2 years was 34%
for B-lineage compared to 57% in T-ALL (p= 0.057) a result
also similar to leukemia free survival (LFS) of 64% in T and
50% in B ALL Ph- negative [15]. The overall CR was 88%
with a relapse rate (RR) of 60% which was comparable to
CR rates reported by others [14,15]. The cumulative DFS at
2 years for the whole study group was 42% in comparison to
64% and 53% reported by others [15,17]. The cumulative
OS at 2 years for the whole studied group was 49% in compar-
ison to 43% at 3-years follow up reported by Larson et al.
(1998) [18]. The cumulative 2-year OS and DFS rates for pa-
tients who achieved and failed CR were similar to others [13].
MRD is one of the most powerful and informative param-
eters to predict relapse and guide clinical management in ALLpatients [2]. In our institution, MRD detection by FCM is rel-
atively accurate, less expensive, applicable for most patients,
rapid and having a sensitivity of at least 10–4–10–5 with Leuke-
mia-speciﬁcity. We found that MRD positivity decreased from
31% (17/55) after induction phase to 13% (15/46) before start
of consolidation to 3% (1/33) before starting maintenance
therapy. A similar decline in the percentage of MRD positivity
when assessed by quantitative PCR was also reported [19]. In
de novo Ph- negative ALL, post induction MRD assessment
(after 2–4 months of treatment) is considered to have the most
important role for evaluation of initial treatment response and
MRD based risk stratiﬁcation. MRD assessment after induc-
tion (after 2 weeks of treatment) additionally identiﬁes patients
with a rapid tumor clearance and a particularly good outcome.
MRD1 in our study showed that 17 patients were high risk
(31%) while 38 patients were low risk (69%) with a cumulative
OS at 2 years of 17% and 65%, respectively (p< 0.001). These
results were almost similar to those reported in GMALL study
with standard-risk ALL who had a rapid decline in MRD
within the ﬁrst month of therapy and had a 0% 3-year RR
[19]. Liu et al. (2006) also found a RR of 50% for MRD posi-
tive and 7% for MRD negative patients at the end of induction
[20].
Twenty-seven patients (47%) were classiﬁed as low (stan-
dard) risk (SR), while 30 patients (53%) were high risk (HR)
according to GMALL risk stratiﬁcation in comparison to
48%, 52%, 34%, 67% respectively reported by others
[10,15]. The 2 years OS were 63% and 35% for the LR and
The Prognostic Signiﬁcance of MRD in Adult Egyptian ALL Patients 141HR groups respectively. The 2 years DFS were 55% and 31%
for LR and HR groups respectively in comparison to 87% for
LR group and 51% for HR groups together in another study
[15].
Concerning post remission monitoring for MRD, the
GMALL proposes 3 monthly intervals for a total of 3 years
as the majority of clinical relapses occur within this time [21]
and reconversion to MRD positivity precedes a clinical relapse
with a median time of 4.1 months between ﬁrst quantiﬁable
MRD and relapse [22]. Our results concur those of the
GMALL study with high MRD (>10–4) at any time-point
associated with a RR of 66–88% [19]. In addition, cumulative
DFS at 2 years was 59% for MRD-LR patients and 17% for
MRD-HR with a 2 year RR of 41% and 83% respectively
(p<0.001), a result similar to that reported by others [23].
However, in our study, DFS was signiﬁcantly correlated with
MRD1 but not with GMALL risk classiﬁcation. Although
OS was correlated with both risk classiﬁcations, the signiﬁ-
cance of FCMMRD1 positivity was higher and more informa-
tive indicating that MRD can serve as a safety net enabling
early reintensiﬁcation in case of MRD based treatment de-
escalation. The use of MRD assessment in risk stratiﬁcation
of adult ALL patients may result in marked improvement in
long term outcomes.
It has been previously reported that high TLC was associ-
ated with worse DFS [24], however in our study no correlation
was found between survival and TLC. Seven (16%) patients
were Ph-positive which was lower than the 20–30% reported
[15,25]. The lower incidence of Ph-positive cases in our study
may be due to lower median age of patients. CR rate in Ph-po-
sitive group (who received conventional chemotherapy not
including high dose methotrexate/cytarabine or imatinib) was
43% in comparison to CR rate of 50% for Ph-positive ALL
treated with imatinib and chemotherapy in another study
[26]. We showed a 2-year OS of 49% achieved by Ph-negative
and 0% by Ph- positive patients (p< 0.001) in comparison to
48% (for patients who achieved 3-log reduction in BCR-ABL
transcripts after consolidation chemotherapy) and 0% for pa-
tients who had less than a 3-log reduction [27]. In Ph-positive
ALL, the value of MRD for initial remission assessment is
more limited in the era of TKI, whereas MRD assessment is
frequently used for post remission monitoring. However, com-
pared with Ph- negative ALL, relapse kinetics are more rapid
with median time between MRD elevation and relapse of only
2- months with [28] and without [29] application of TKI.
In conclusion, MRD1 risk classiﬁcation in adult ALL
shows strong correlation with disease response and outcome
in terms of DFS and OS. Our results support the usefulness
of assessing MRD in patients with ALL by means of FCM; be-
cause this method is applicable to all cases and is a good op-
tion to classify and follow-up patients to decide timely
therapeutic interventions. In this context, MRD can also be
considered as quantitative and objective extension of estab-
lished end points of hematologic remission and relapse more
than a substitute of pretherapeutic risk factors.
References
[1] Bruggemann M, Raff T, Kneba M. Has MRD monitoring
superseded other prognostic factors in ALL? Blood
2012;120(23):4470–81.[2] Campana D. Role of minimal residual disease monitoring in
adult and pediatric acute lymphoblastic leukemia. Hematol
Oncol Clin North Am 2009;23(5):1083–98.
[3] Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B,
et al. Improved risk classiﬁcation for risk speciﬁc therapy based
on molecular study of minimal residual disease (MRD) in adult
acute lymphoblastic leukemia (ALL). Blood 2009;113(18):
4153–62.
[4] Borowitz MJ, Devidas M, Hunger SP, BowmanWP, Carroll AJ,
Linda S, et al. Clinical signiﬁcance of minimal residual disease
childhood acute lymphoblastic leukemia and its relationship to
other prognostic factors: a Children’s Oncology Group study.
Blood 2008;111(12):5477–85.
[5] Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY, et al.
Risk factors for adults with Philadelphia chromosome positive
acute lymphoblastic leukemia in remission treated with
allogeneic bone marrow transplantation: the potential of real
time quantitative reverse transcription polymerase chain
reaction. Br J Haematol 2003;120(1):145–53.
[6] Campana D. Minimal residual disease in acute lymphoblastic
leukemia. The education program of American Society of
Hematology 2010, 7–12.
[7] Cazzaniga G, Valseccki MG, Gipa G, Conter V, Biondi A.
Deﬁning the correct role of minimal residual disease tests in the
management of acute lymphoblastic leukemia. Br J Haematol
2011;155(1):45–52.
[8] Kaleem Z, Crawford E, Pathan MH, Jasper L, Covinsk MA,
Johnson LR, et al. Flow cytometric analysis of acute leukemias.
Diagnostic utility and critical analysis of data. Arch Pathol Lab
Med 2003;127(1):42–8.
[9] Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A,
Maglia O. Standardization of ﬂow cytometric minimal residual
disease evaluation in acute lymphoblastic leukemia; multicentric
assessment is feasible. Cytometry B Clin Cytom
2008;74(6):331–40.
[10] Hoelzer D, Go¨kbuget N, Ottmann O, Pui CH, Relling MV,
Appelbaum FR, et al. Acute lymphoblastic leukemia.
Hematology (Am Soc Hematol Educ Program) 2002:162–92.
[11] Van Dongen JJM, Szczepanski T, Van der Velden. Minimal
residual disease. I. In: Kaspers GJL, Coifﬁer B, Heinrich MC,
Estey E, editors. Innovative leukemia and lymphoma therapy
2008. New York: Informa Health care; 2008. p. 45–84, ISBN-
10 0-8493-5083-2; ISNB13987-0-8493-5083-2.
[12] Norusis M: SPSS 17.0 advanced statistical procedures
companion. Upper Saddle-River, N.J. 2009: Prentice Hall, Inc.
[13] Go¨kbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR,
Freund M, et al. Treatment of adult ALL according to the
protocols of the German Multicenter Study Group for Adult
ALL (GMALL). Hematol Oncol Clin North Am
2000;14(6):1307–25.
[14] Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH,
Richards SM, et al. Induction therapy for adults with acute
lymphoblastic leukemia: results of more than 1500 patients from
the international ALL trial: MRC UKALL XII/ECOG E2993.
Blood 2005;106(12):3760–7.
[15] Abdel Hamid TM, Mahmoud KH, Kamel AM, El Sharkawy N
et al.: Risk adapted chemotherapy treatment for adult acute
lymphoblastic leukemia. Egypt J Haematol 2005, 30:579.
[16] Larson RA, Dodge RK, Burns CP, Lee EV, Stone RM,
Schulman P, et al. A ﬁve-drug remission induction regimen
with intensive consolidation for adults with acute lymphoblastic
leukemia: cancer and leukemia group B study 8811. Blood
1995;85:2025–37.
[17] Mahmoud HK, Hamza MR. Gad El Mawla N, Khaled HK,
Elzawahry H, Abdelhamid T etal: the impact of intensiﬁed
induction protocol on remission rate and duration in adult acute
lymphoblastic leukemia. Egypt J Haematol 1995;20:225.
142 M.A. Samra et al.[18] Larson RA, Dodge RK, Linker CA, Stone RM, Powel BL, Lee
EV, et al. A randomized controlled trial of ﬁlgrastim during
remission induction and consolidation chemotherapy for adults
with acute lymphoblastic leukemia: CALGB study 9111. Blood
1998;92(5):1556–64.
[19] Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M,
Droese J, et al. Clinical signiﬁcance of minimal residual disease
quantiﬁcation in adult patients with standard-risk acute
lymphoblastic leukemia. Blood 2006;107(3):1116–23.
[20] Liu YR, Chen SS, Chang Y, Fu JY, Zhang LP, Wang H
Leukemia-associated immunophenotypes in 415 patients with B-
ALL by multiparametric ﬂow cytometry analysis. Zhogguo Shi
Yan Xue Ye Xue Za Zhi 2006:853–7.
[21] HuguetF,LeguayT,RaffouxE,ThomasX,BeldjordK,Delabesse
E, et al. Pediatric inspired therapy in adults with Philadelphia
chromosome negative acute lymphoblastic leukemia; the
GRAALL-2003 study. J Clin Oncol 2009;27(6):911–8.
[22] Go¨kbuget N, Raff R, Brugge-Mann M, Flohr T, Scheuring V,
Pfeifer H, et al. Risk/MRD adapted GMALL trials in adult
ALL. Ann Hematol 2004;83(Suppl 1):S129–31.
[23] Willemse MJ, Seriu T, Hettinger K, d’ Aniello E, Hopw C,
Panzer-Grumaver ER, et al. Detection of minimal residual
disease identiﬁes differences in treatment response between T-
ALL and precursor-B-ALL. Blood 2002;99:4386–93.
[24] Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S,
et al. Long-term follow-up results of hyperfractionatedcyclophosphamide, vincristine, doxorubicin, and dexamethasone
(Hyper-CVAD), a dose-intensive regimen, in adult acute
lymphocytic leukemia. Cancer 2004;101:2788–801.
[25] Hoelzer D, Go¨kbuget N: Treatment of elderly patients with
acute lymphoblastic leukemia. ASCO Education Book 2005,
41st Annual Meeting May 13–17:533–539.
[26] Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J,
Stelljes M, et al. Alternating versus concurrent schedules of
Imatinib and chemotherapy as front-line therapy for
Philadelphia-positive acute lymphoblastic leukemia (Ph+
ALL). Blood 2006;108:1469–77.
[27] Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C,
et al. Signiﬁcant reduction of the hybrid BCR/ABL
transcripts after induction and consolidation therapy is a
powerful predictor of treatment response in adult Philadelphia-
positive acute lymphoblastic leukemia. Leukemia 2005;19(4):
628–35.
[28] Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Veda
Y, et al. Prospective monitoring of BCR-ABL1 transcripts
levels in patients with Philadelphia chromosome positive acute
lymphoblastic leukemia undergoing imatinib combined
chemotherapy. Br J Haematol 2008;143(4):503–10.
[29] Raddish J, Gehy G, Lee A, Avery R, Bryant E, Edmands S,
et al. Detection of BCR-ABL transcript in Philadelphia
chromosome positive acute lymphoblastic leukemia after
marrow transplantation. Blood 1997;89(7):2602–9.
